Edrissian G H, Afshar A, Sayedzadeh A, Mohsseni G, Satvat M T
School of Public Health, Teheran University of Medical Sciences, Iran.
J Trop Med Hyg. 1993 Aug;96(4):237-40.
Studies of drug resistance of Plasmodium falciparum cases from SE Iran were carried out in vivo and in vitro during 1990-91. In a study of 26 chloroquine-resistant infections, using amodiaquine (25 mg kg-1 over 3 days), followed by two-thirds of the standard dose of sulphadoxine-pyrimethamine, six cases were resistant at the RI(3) and RII(3) levels. An additional study testing the standard dose of sulphadoxine-pyrimethamine in 43 chloroquine-resistant cases revealed five (11.6%) resistant at the RI(2) and RII(3) levels. Six of the above resistant infections were contracted in Hormozgan, three in Sistan-Baluchestan, one in Kerman provinces of Iran and one in Pakistan. In five of 22 successful in-vitro tests, carried out on different isolates, the parasites grew to schizonts (> or = 8 nuclei) in the wells containing 1000 pmol sulphadoxine and 12.5 pmol pyrimethamine, indicative of resistance.
1990 - 1991年期间，在伊朗东南部对恶性疟原虫病例进行了体内和体外耐药性研究。在一项针对26例氯喹耐药感染病例的研究中，使用氨酚喹（3天内25毫克/千克），随后给予三分之二标准剂量的周效磺胺 - 乙胺嘧啶，有6例在RI(3)和RII(3)水平耐药。另一项针对43例氯喹耐药病例测试标准剂量周效磺胺 - 乙胺嘧啶的研究显示，有5例（11.6%）在RI(2)和RII(3)水平耐药。上述耐药感染病例中，6例在霍尔木兹甘感染，3例在锡斯坦 - 俾路支斯坦感染，1例在伊朗克尔曼省感染，1例在巴基斯坦感染。在对不同分离株进行的22次成功体外试验中，有5次试验里，寄生虫在含有1000皮摩尔周效磺胺和12.5皮摩尔乙胺嘧啶的孔中发育成裂殖体（≥8个核），表明存在耐药性。
